Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027

30 August 2018
Pharma

A new report by visiongain forecasts the world IVD market will reach $122.9bn in 2027. That revenue prediction and others appear in Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia published in November 2016. Visiongain is a business information publisher and consultancy in London, UK.

Visiongain estimates that in 2016, Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 41.5% of the global IVD market with combined revenue of $25.7bn

This report analyses the leading companies operating in the in vitro diagnostics (IVD) market. It aims to provide a comprehensive review of those companies, looking at their IVD products, financial performance, deals with other drug developers and future outlooks. The study examines opportunities and challenges in the industry and market for IVD products, as well as strategies for future growth. To provide context for the company profiles, this report also contains analysis of the world IVD market. An estimate for the market size is provided for 2016, and overall market revenues are forecasted for the period 2017 to 2027. Additionally, there is an analysis of the leading IVD segments.

The report focuses on these main segments of the market:

• Clinical Chemistry
• Immunochemistry
• Haematology
• Microbiology
• Genetic Testing
• Point-of-Care

This 185 page report provides:

• Most recent profiles of top In Vitro Diagnostic American Companies with updated revenues and forecast for the period 2017-2027

• Most recent profiles of top In Vitro Diagnostic European Companies with updated revenues and forecast for the period 2017-2027

• Most recent profiles of top In Vitro Diagnostic Asian Companies with updated revenues and forecast for the period 2017-2027

• Enhanced detail analysis of what stimulates and restrains that industry and market.

• 75 figures and 65 tables.

Recent News

“Precision Medicine Market is Poised to Surpass US$67 billion in 2020” says new Visiongain report

Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.

27 May 2020

Read

Visiongain publishes Colon Targeting Drug Delivery Market Report 2020-2030

The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.

27 May 2020

Read

“The global automation in biopharma market is estimated to reach USD 1.23 billion by 2025” says new Visiongain report

The automation in biopharma industry market is estimated to grow at a CAGR of 4.3% over the forecast period.

22 May 2020

Read

“Erectile Dysfunction Market is projected to surpass US$2.5 billion in 2020” says new Visiongain report

The global erectile dysfunction is in a transition phase as the majority of the consumers are shifting from traditional pharmaceuticals to herbal-based products pertaining to lesser side effects and positive perception of natural products amongst the society. Visiongain understands this market to be dynamic, with a large number of players to enter the market.”

07 May 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever